Novartis Shares Drop Over 10% After Third Drug Trial Failure
Novartis shares fell more than 10% on Tuesday after its del-desiran drug for a muscle-wasting disorder failed in a late-stage clinical trial. This marks the third consecutive drug trial disappointment for Novartis within one week, intensifying investor concerns about the company's pipeline and future growth prospects. The failure of this latest trial has raised questions over the reliability of Novartis' upcoming therapies and could impact its strategic plans to expand in key therapeutic areas. The stock was last seen down by 10%, reflecting a sharp market reaction to these setbacks, which have occurred at an accelerated pace within just days. Investors are now closely watching how management will respond to the string of failures and whether there is any potential for alternative successes or strategic adjustments in their drug development approach.
Tickers: $NVS